Contraindications: Testosterone Suspension is contraindicated in individuals with known hypersensitivity to testosterone or any component of the aqueous carrier. It must not be used by individuals diagnosed with prostate carcinoma, breast cancer, or severe untreated benign prostatic hyperplasia. Pregnancy and breastfeeding are absolute contraindications. Individuals with severe hepatic impairment, uncontrolled polycythaemia, or active thromboembolic disease should not use this compound.
Side_Effects: Due to the absence of an ester buffer and the resulting sharp plasma peaks, androgenic side effects — acne, oily skin, accelerated scalp hair loss in genetically predisposed individuals — may manifest more abruptly than with esterified forms. Oestrogen-mediated effects (water retention, gynaecomastia) remain possible via aromatisation; an aromatase inhibitor (e.g. Anastrozole or Exemestane) should be kept available. Frequent injection-site reactions (pain, swelling, nodule formation) are common with aqueous suspensions and should be managed through strict rotation protocols.
Monitoring: Full blood count (haematocrit, haemoglobin), serum LH/FSH, liver enzyme panel (ALT/AST), and lipid profile should be assessed at baseline and every 6–8 weeks during use. Serum PSA should be monitored in users over 40. Blood pressure monitoring is recommended throughout the cycle given the compound's rapid action on fluid and electrolyte balance.
PCT: Post-cycle therapy is mandatory following any Testosterone Suspension protocol. Because the compound clears within 24–48 hours of the last injection (no ester half-life to account for), PCT can begin within 24–72 hours. A standard SERM-based protocol — Clomiphene 50 mg/day for 2 weeks followed by 25 mg/day for 2 weeks, or Tamoxifen 20 mg/day for 4 weeks — is commonly applied to restore endogenous HPG axis function.